Global Stirred Tank Bioreactor Market Anticipated to Reach US$ 4,148.0 Million by 2032

According to a recent market study published by Growth Market Reports, titled, “Global Stirred Tank Bioreactor Market by type, by Capacity, by application, by end user, and by region: Size, Share, Trends and Opportunity Analysis, 2017-2032”, the market was valued at US$ 1,962.5 Million in 2023 and is anticipated to grow at a growth rate of 8.9% by the year 2032.

Get Sample Report @ https://growthmarketreports.com/request-sample/7208

A Stirred Tank Bioreactor (STR), also called as mixing tank bioreactor, is a closed vessel designed to provide controlled environment for cultivating biological materials such as cells, microorganisms, or tissues. STR offers a medium that provides nutrients for cells to grow in and deliver sufficient mixing and aeration to the culture to encourage growth.

The global stirred tank bioreactor market has been segmented in terms of by type, by Capacity, by application, by end-user, and by region

On the based-on Type, the stirred tank bioreactor market is segmented into microbial bioreactors/fermenters, cell culture bioreactors, single-use/disposable bioreactors, and bioreactors for special applications. The microbial bioreactors/fermenters segment is expected to hold a significant share of 28.8% during the forecast period, as it is a key method for producing enzymes used in various industries, such as food processing and biocatalysis.

Based on capacity, the stirred tank bioreactor market is segmented into less than 10L, 11L-20 L, 21L-30L, and more than 30L. The less than 10L segment registers a substantial share of the market in the coming years, as it is widely used in universities, research institutions, and biotechnology companies. Companies utilize small-scale STRs for initial research, feasibility studies, and cell line development. Increase in investments in life sciences research fuels the demand for benchtop models.

On the basis of application, the stirred tank bioreactor market is segregated into antibodies, viral vectors, cell therapies, and others. The antibodies segment is expected to hold a significant share of the market during the forecast period, as STRs are widely used for antibody-based therapeutics. Monoclonal antibodies are used to treat various diseases such as cancer, autoimmune disorders, and infectious diseases.

In terms of end-user, the stirred tank bioreactor market is fragmented into pharmaceutical and biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). The pharmaceutical and biopharmaceutical companies’ segment is expected to grow at a substantial CAGR during the forecast period, due to the rising demand of STRs in pharmaceutical and biopharmaceutical companies. Pharmaceutical companies are constantly investing in the R&D of novel biopharmaceuticals, leading to a need for STRs for pilot-scale production and clinical trials.

The outbreak of Coronavirus disease in 2019 (COVID-19) hampered the global economy, increased global interdependence, and tested the governments of various countries. The COVID-19 pandemic had a significant impact on a wide range of industries worldwide. The pandemic caused massive supply chain disruptions, which impacted product production and distribution.

The COVID-19 pandemic propelled the stirred-tank bioreactor market. The high need to develop and manufacture vaccines against COVID-19 significantly boosted the demand for cell culture bioreactors. Bioreactors are essential for large-scale production of viral vectors or cells used in vaccine development.

Bioreactor sales grew significantly during 2020 with many companies expanding their facilities to fulfil the demand for COVID-19 vaccine production. Nationwide vaccination programs throughout the world and the ongoing demand further boost sales in the near future.

In September 2021, ABEC, a leading provider of integrated solutions for biopharma companies, delivered 6 bioreactors to Pune-based Serum Institute of India to speed up the production of the Novavax’ COVID-19 vaccine. Serum Institute had announced that it plans to use ABEC’s single-use technology to accelerate the supply of NVX CoV2373 through India and other low- and middle-income countries.

As per growth market reports by industry Senior Associate “Anuradha More”, “The expanding application market, healthcare, and medical device industry are expected to contribute to the growth of the global Stirred Tank Bioreactor market.

Key Takeaways from the Study:

• The players in the global Stirred Tank Bioreactor market ABEC; Bailun Biotechnology Co.,Ltd; BRS Biotech OÜ; Danaher Corporation (Cytiva); Eppendorf SE; Esco VacciXcell; MDX Biotechnik International GmbH; Merck KGaA; Sartorius AG; Thermo Fisher Scientific Inc; and Other. These companies hold a significant share of the global Stirred Tank Bioreactor market in 2023.

• The 21L-30L segment was valued at USD 538.5 million in 2023, and is projected to expand at a CAGR of 9.0% during the forecast period. It is suitable for small-batch production of high-value biopharmaceuticals, personalized medicine therapies, or bioproducts. CMOs offering biomanufacturing services for biotech companies often utilize 21L-30L size range for production runs.

• Furthermore, the 21L-30L segment was valued at USD 538.5 million in 2023, and is projected to expand at a CAGR of 9.0% during the forecast period. It is suitable for small-batch production of high-value biopharmaceuticals, personalized medicine therapies, or bioproducts. CMOs offering biomanufacturing services for biotech companies often utilize 21L-30L size range for production runs.

• The contract development and manufacturing organizations (CDMOs) segment is anticipated to expand at a significant share of the market during the forecast period, due to the growing outsourcing trend. Many pharmaceutical and biotech companies outsource biomanufacturing to CDMOs due to factors such as cost-effectiveness, expertise, and access to advanced technologies such as large-scale STRs. Increasing focus on developing biologics requiring complex manufacturing processes, is driving the demand for CDMO expertise with STRs.

• In terms of regions, the global Stirred Tank Bioreactor markets are divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in Asia Pacific is projected to expand at a CAGR of 9.3% during the forecast period, due to government initiatives, supportive policies, and a growing talent pool are attracting investments in biopharmaceutical research and development. Biopharmaceuticals manufacturers in the APAC region offers cost advantages due to lower labor costs and operational expenses. This propels to establish or expand biomanufacturing facilities in the region, driving the demand for STRs. Asia pacific is also growing emphasis on adopting advanced bioprocessing technologies, including next-generation STRs.

Report Scope:

Target Audience:

• Supply-side: Manufacturer, Distributors, Supplier.

• Demand Side: Healthcare, Hospitals, Ambulatory Surgical Centers and Others.

• Regulatory Side: Concerned government authorities, and other approved governing bodies.

• Associations and Industry Bodies: World Health Organization (WHO), Food Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), National Health Expenditure (NIH) etc.